Farther Finance Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Farther Finance Advisors’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-35	Closed	-$18	–	4468
2024 Q4	$18	Sell	35 -29	-45%	-$83	﹤0.01%	3939
2024 Q3	$239	Hold	64	–	–	﹤0.01%	3610
2024 Q2	$354	Sell	64 -24	-27%	-$105	﹤0.01%	3354
2024 Q1	$420	Sell	88 -4	-4%	-$22	﹤0.01%	3069
2023 Q4	$481	Buy	+92	New	+$908	﹤0.01%	2989

Other funds holding EGRX

SLG

Stanley-Laman Group Berwyn, Pennsylvania $984M AUM 72.08% 1-Year Est. Return

AIC

Archer Investment Corporation Carmel, Indiana $522M AUM 26.29% 1-Year Est. Return

Farther Finance Advisors's EGRX Position: Q1 2025 in Review

Farther Finance Advisors sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2025, closing a stake of 35 shares — an estimated $18 sold.

Farther Finance Advisors first reported a position in EGRX in Q4 2023 and held it in 5 quarters. The position peaked at $481 in Q4 2023. 2 funds tracked by Wall St. Rank hold EGRX as of Q1 2025.

Farther Finance Advisors reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2025 after selling out during the quarter.
Farther Finance Advisors sold 35 Eagle Pharmaceuticals, Inc. shares in Q1 2025, an estimated $18.
Farther Finance Advisors first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2023 and held it in 5 quarters.
Farther Finance Advisors's Eagle Pharmaceuticals, Inc. position peaked at $481 in Q4 2023.
2 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2025.

Based on Farther Finance Advisors's 13F filing for Q1 2025, filed 14 Apr 2025.